To Study the Individual Variants of Chemotherapy-Induced Neurotoxicity

Neurotoxicity Syndromes Clinical Trial

Official title:
Integrating Clinical and Genomic Profiles for Prediction and Prevention of Chemotherapy-induced Neuropathy Via Big Bio-Data Analytics

Status Active, not recruiting

Clinical Trial Summary

To study the risk prediction of chemotherapy-induced peripheral neuropathy (CIPN) by the clinical bioinformatics and genomic profile.

Clinical Trial Description

This is a prospective, observational, cohort study, monitoring the chemotherapy-induced peripheral neurotoxicity by traditional clinical scales, neurological examinations, and semi-quantitative assessments. Moreover, all the genetic changes will be analyzed by next generation sequencing and we will try to identify relevant variants in individuals who suffer from chemotherapy-induced neurotoxicity. ;

Study Design

Related Conditions & MeSH terms

Neurotoxicity Syndromes

Clinical Trial Details

NCT number	NCT02481336
Study type	Observational
Source	National Cheng-Kung University Hospital
Contact
Status	Active, not recruiting
Phase
Start date	March 2015
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04150913` - A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity	Phase 2
Terminated	`NCT03954106` - A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity	Phase 2
Withdrawn	`NCT00389259` - Scopolamine Treatment for Patients With Organophosphate Poisoning	N/A
Terminated	`NCT00176553` - A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity	N/A